-
Cost-Effectiveness of Sulopenem vs. Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Decision Analysis
Sep 9, 2025, 16:22 PM -
Workforce and Environmental Impact of Home-Based vs. Hospital-Based Administration of Second-Line MS Therapies in the Netherlands: A Comparative Analysis of Personnel Time and Carbon Footprint
Sep 9, 2025, 16:22 PM -
Challenges in the German AMNOG Procedure: The Need for National PICO Transparency and Optimized Consultation Windows in the Context of EU-HTA
Sep 9, 2025, 16:22 PM -
Effectiveness of Psychosocial Interventions for Adults With Substance Use Disorder and Co-Occurring Mental Health Disorder: An Umbrella Review
Sep 9, 2025, 16:22 PM -
Development and Validation of a Machine Learning Model for Predicting French HAS ASMR Ratings Using Product and Disease Characteristics
Sep 9, 2025, 16:22 PM -
Unmet Need in IgA Nephropathy (IgAN): Disparity Between Clinical Guidelines and Real-World Practice in Ireland
Sep 9, 2025, 16:22 PM -
From Admission to Discharge: Understanding the Transplant Patient Journey With German Statutory Health Insurance Claims Data
Sep 9, 2025, 16:22 PM -
Qualitative Trial Interviews to Explore the Experience of Adult and Pediatric Patients Participating in a Pivotal Phase 3 Trial of DTX401 for Glycogen Storage Disease Type Ia
Sep 9, 2025, 16:22 PM -
Laboratory Testing Patterns in Patients With Breast Cancer Treated With CDK4/6 Inhibitors: A Multi-Country Electronic Health Record Study From the UK, Germany, and Japan
Sep 9, 2025, 16:22 PM -
Are We Measuring What Matters in Postpartum Depression Trials?
Sep 9, 2025, 16:22 PM -
A Conceptual Paper on Integrating a Pharmacometric Multistate Model With Cost-Effectiveness Analysis for Infectious Diseases Treatment Optimization
Sep 9, 2025, 16:22 PM -
The Role of Body Fat in the Regulation of Male Fertility
Sep 9, 2025, 16:22 PM -
Indirect Treatment Comparison of Biochemical Control Between Pasireotide Long-Acting Release and Pegvisomant as Second-Line Therapies for Acromegaly, Based on Real-World Evidence
Sep 9, 2025, 16:22 PM -
Economic Impact of Lenalidomide-Refractory Multiple Myeloma in Finland: Insights From Real-World Data
Sep 9, 2025, 16:22 PM -
Validation Between Antidepressant Treatment Failure Proxy and PHQ-9 Score in Major Depressive Disorder Using a Linked Insurance Claims and Electronic Health Record Dataset
Sep 9, 2025, 16:22 PM -
Real-World Healthcare Resource Utilization and Costs by Glycemic Control in People With Type 2 Diabetes: An Observational Population-based Register Study in Sweden
Sep 9, 2025, 16:22 PM -
Building the Bridge to Access: Leveraging RWE From Early Access Schemes to Reimbursement in Gene and Cell Therapies
Sep 9, 2025, 16:22 PM -
Towards Quantifying the Impact of Hypofractionation vs. Standard Radiotherapy Treatment Regimens for Cancer on Costs Workflow and the Environment
Sep 9, 2025, 16:22 PM -
Healthcare Resource Use and Direct Healthcare Costs Associated With Respiratory Syncytial Virus Infections in Individuals Aged 18 Years or Older in Italy: A Retrospective Observational Study
Sep 9, 2025, 16:22 PM -
Estimated Long-Term Healthcare Cost Savings From EVP Use in the UK
Sep 9, 2025, 16:22 PM
